C-suite execs are paying surgeons big money to look fresh-faced, approachable, and less irritable

Facial cosmetic procedures rose 25% from 2019 to 2024; blepharoplasty and facelifts were among the top procedures in 2024 with 67,559 eyelid surgeries and 46,446 facelifts in the 55–69 age group. Plastic surgeons report a notable uptick in C-suite clients—one NYC surgeon says his male client share doubled, a Beverly Hills surgeon estimates ~50% of his executive patients are from tech—and typical pricing ranges from about $3.9k–$20k for common facial tweaks to facelifts starting at $120k (neck lifts $85k+). The trend aligns with a younger C-suite (incoming CEOs in their 60s fell to 18% in 2025; average age of new CEOs dropped from 55.8 to 54.4), driving demand for eyelid lifts, brow lifts, and eye-bag removals.

Analysis

Demand from image-sensitive executives is creating a concentrated, high-margin growth pocket inside elective aesthetics that favors providers with durable, repeatable consumables and ambulatory delivery channels rather than one-off, high-capex hospital procedures. That favors manufacturers of minimally invasive energy devices and single-use implants/sutures, and operators of ASC-style clinics that can scale throughput; the revenue model shifts from episodic big-ticket sales to recurring, scheduler-driven cash flows over multiple visits.

A non-obvious governance effect: easier cosmetic rejuvenation lowers the signaling value of age and may materially lengthen tenures for incumbent CEOs who would otherwise face turnover or activist pressure tied to generational leadership transitions. Expect a modest reduction in activist-related turnover and potentially slower C-suite refresh cycles over the next 12–36 months in sectors where public visibility matters most (media, tech, finance), which changes the timing of strategy- or leadership-driven re-rating opportunities.

Key near-term reversals are macro-driven: elective procedures are discretionary and vulnerable to a growth slowdown within quarters, while longer-term risk comes from true noninvasive alternatives and regulatory/legal shocks that could compress margins and traffic. The durable alpha sits with companies that capture recurring per-procedure consumable spend and own the outpatient distribution footprint; avoid exposure to single-product, binary regulatory stories and to businesses whose revenue depends on a small cadre of superstar surgeons or celebrity endorsements.

Key Decisions for Investors

• Long INMD (InMode) 12-month call spread: buy 12–18 month calls and sell higher-strike calls to limit premium spent. Rationale: captures durable shift to minimally invasive ambulatory procedures and recurring device consumable sales. Risk/reward: asymmetric upside if procedure volumes continue to re-shore to ASCs; downside limited to premium if elective demand drops in a macro slowdown.
• Buy ABBV (AbbVie) stock or a 9–12 month covered-call position: provides defensive cash flow exposure to esthetic pharma products and hedges device-only exposure. Rationale: diversifies aesthetics exposure into high-margin, branded injectables with sticky demand. Risk/reward: modest yield and downside protection versus pure-play aesthetics names; regulatory headline risk is main downside.
• Pair trade — Long INMD / Short EOLS (Evolus) over 6–18 months: go long device-focused operator, short single-product neurotoxin vendor. Rationale: devices capture recurring per-procedure spend and clinic adoption; single-product players are binary on product cycles and pricing pressure. Risk/reward: earns alpha if clinic throughput rises and neurotoxin pricing or share faces pressure; downside if neurotoxins outcompete devices or a safety event hits devices.
• Macro hedge: buy 3–6 month puts on consumer discretionary exposure (XLY) to protect portfolio against a sharp pullback in elective spending. Rationale: elective aesthetic demand is cyclic; a near-term recession would compress volumes quickly. Risk/reward: small cost for insurance against a concentrated demand shock.